BIOMAT Database Logo BIOMAT Database Logo

Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year. 1998

G F Cooney, and V Jeevanandam, and S Choudhury, and G Feutren, and E A Mueller, and H J Eisen
Temple University Hospital, Philadelphia, PA, USA. daycooney@aol.com

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

G F Cooney, and V Jeevanandam, and S Choudhury, and G Feutren, and E A Mueller, and H J Eisen
Relative bioavailability of Sandimmune and Sandimmune Neoral in pediatric liver recipients.
October 1994, Transplantation proceedings,
G F Cooney, and V Jeevanandam, and S Choudhury, and G Feutren, and E A Mueller, and H J Eisen
Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group.
December 1999, Therapeutic drug monitoring,
G F Cooney, and V Jeevanandam, and S Choudhury, and G Feutren, and E A Mueller, and H J Eisen
Conversion from Sandimmune to Neoral in renal transplant recipients: two-year experience.
August 1998, Transplantation proceedings,
G F Cooney, and V Jeevanandam, and S Choudhury, and G Feutren, and E A Mueller, and H J Eisen
Conversion from Sandimmune to Neoral in organ transplant recipients.
December 1998, Journal of transplant coordination : official publication of the North American Transplant Coordinators Organization (NATCO),
G F Cooney, and V Jeevanandam, and S Choudhury, and G Feutren, and E A Mueller, and H J Eisen
Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients.
November 1998, Transplantation proceedings,
G F Cooney, and V Jeevanandam, and S Choudhury, and G Feutren, and E A Mueller, and H J Eisen
Changing stable heart transplant recipients from Sandimmune to Neoral.
August 1996, Transplantation proceedings,
G F Cooney, and V Jeevanandam, and S Choudhury, and G Feutren, and E A Mueller, and H J Eisen
Conversion from Sandimmune to Neoral in stable heart transplant recipients.
August 1996, Transplantation proceedings,
G F Cooney, and V Jeevanandam, and S Choudhury, and G Feutren, and E A Mueller, and H J Eisen
Experience with neoral versus sandimmune in primary liver transplant recipients.
January 1998, Transplant international : official journal of the European Society for Organ Transplantation,
G F Cooney, and V Jeevanandam, and S Choudhury, and G Feutren, and E A Mueller, and H J Eisen
Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients.
August 1996, Transplantation proceedings,
G F Cooney, and V Jeevanandam, and S Choudhury, and G Feutren, and E A Mueller, and H J Eisen
Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.
August 1996, Transplantation proceedings,
Copied contents to your clipboard!